Gene Editing Startup Beam Therapeutics Launches With $87M in Series A Funds

May 17, 2018

|

NEW YORK (GenomeWeb) – Beam Therapeutics announced today that it has launched with $87 million in Series A funding to develop precision genetic medicines that make edits to individual base pairs in the genome.

The funding round was led by F-Prime Capital Partners and ARCH Venture Partners.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Not a Unique Challenge Anymore

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Case Goes On

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

The Very Old, Very Young, and Very Talented

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

This Week in PLOS

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.

Main menu